After completing the 12-month PGY-2 Clinical Pharmacogenomics (PGx) Residency at Mayo Clinic, you will possess comprehensive clinical knowledge and skills to provide high-quality, advanced pharmacogenomics care in multiple clinical disciplines.
The purpose of the PGY-2 Clinical Pharmacogenomics Residency at Mayo Clinic is to build on Doctor of Pharmacy (PharmD) education and PGY-1 pharmacy residency programs to contribute to the development of clinical pharmacists in specialized areas of practice. PGY-2 residencies provide you with opportunities to function independently as a practitioner by conceptualizing and integrating accumulated experience and knowledge and incorporating both into the provision of patient care or other advanced practice settings. Residents who successfully complete an accredited PGY-2 pharmacy residency are prepared for advanced patient care, academic, or other specialized positions, along with board certification, if available.
PGY-2 training at Mayo Clinic will provide you with opportunities to grow as a future PGx specialist by integrating knowledge and experience into the provision of PGx implementation and patient care. To prepare for this professional growth, training is focused on integrating PGx into comprehensive patient care, practice management, and PGx research.
This educational experience occurs in a complex, quality- and teaching-oriented practice setting with a diverse patient population. Preceptors are dedicated to patient care, teaching, and the advancement of the practice and profession of pharmacy.
Resident experiences include:
- Develop expertise, knowledge, and skills in multiple areas of PGx through a challenging curriculum
- Contribute to an interdisciplinary health care team by participating in direct and indirect care of patients with PGx results
- Design and manage therapeutic regimens, establishing outcomes, and providing clinical recommendations based on national and international PGx guidelines
- Participate in quality assurance and performance improvement committees and projects dedicated to maintaining institutional and regulatory standards
- Provide drug information to the interdisciplinary team in an environment based on teamwork and mutual respect
- Help provide high quality clinical care using evidence-based gene-drug guidelines to improve medication experience and decrease potential adverse drug interactions
- Enhance skills in conducting clinical research and quality improvement projects
- Serve as a co-preceptor for pharmacy trainees for their PGx rotations
- Strengthen communication skills to health care professionals, residents, students, patients, and their caregivers to optimize drug therapy outcomes and care experience
The PGY-2 Clinical Pharmacogenomics Residency at Mayo Clinic is currently in candidate status by the American Society of Health-System Pharmacists (ASHP). One candidate a year is selected on a competitive basis.
The Mayo Clinic campus in Rochester, Minnesota, where more than 1.3 million patients are seen annually, includes extensive outpatient facilities. This Mayo Clinic site is among the largest, most advanced medical centers in the world. The campus consists of approximately 30 buildings. The Mayo Building and Gonda Building serve as the central area for physician offices, examination rooms, and procedure rooms.
Education for the PGY-2 PGx pharmacy residency takes place at Mayo Clinic — Rochester, including the Saint Marys campus (1,265 beds), Methodist campus (794 beds), or one of the many ambulatory care clinics. Additionally, the Department of Pharmacy works closely with Mayo Clinic’s Center of Individualized Medicine. This center is organized into two interwoven groups of programs. The translational program brings discoveries to patient care, and the infrastructure program provides technical resources, expertise, and services to ensure information is available to all medical providers, wherever the patient may be. More information on Mayo Clinic’s pharmacogenomics program can be found here.